Please join me in contacting your Connecticut State Legislators and asking them to support Senate Bill 1007 which expands access to obesity treatments like bariatric surgery and FDA approved obesity medicaitons.
Bottle of Lies: The Inside Story of the Generic Drug Boom
Bariatric surgery has emerged as an effective means of reducing weight in morbidly obese individuals, while also significantly improving diabetes. Currently, laparoscopic sleeve gastrectomy (LSG)…
Obesity has become a pressing worldwide health issue, with rates steadily rising over recent decades. Beyond its well-documented associations with physical health issues, such as…
Some payers are imposing further restrictions or eliminating coverage of GLP-1 drugs while either maintaining access to bariatric surgery or making it easier to obtain.
This pooled analysis including 4 trials examines the long-term glycemic control and safety of bariatric surgery compared with medical/lifestyle management of type 2 diabetes.
Annual price of semaglutide would have to drop significantly to be comparable
This economic evaluaton study assesses the cost-effectiveness of semaglutide compared with endoscopic sleeve gastroplasty over 5 years for individuals with class II obesity.
Annual price of semaglutide would have to drop significantly to be comparable
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic liver disease worldwide. In this review, Tincopa et al. highlight challenges and potential solutions in drug…
Nature Metabolism – Klingelhuber, Frendo-Cumbo et al. develop a proteomic atlas elucidating the intracellular spatiotemporal changes in protein levels and localizations during human adipogenesis.
